文献速递关节外科

John N. Insall 奖:MARCQI 疼痛控制优化路径(POP):注册数据与教育对阿片类药物使用的影响

John N. Insall Award: MARCQI's Pain-Control Optimization Pathway (POP): Impact of Registry Data and Education on Opioid Utilization.
PubMed 文献 · J Arthroplasty · 2022-03-08

本研究利用 MARCQI 数据库,分析 2018 年 1 月至 2019 年 12 月期间 84,998 例初次关节置换术患者出院时口服吗啡当量(OME)处方量,比较密歇根州阿片类药物法律实施前后及 MARCQI 推荐发布前后的变化。结果显示所有组别及所有时间段处方量均显著下降(P < .001),从收集首月至末月,全髋关节置换术阿片类药物初治患者 OME 下降 47.1%,阿片类药物耐受患者下降 53.4%;全膝关节置换术相应下降 48.3% 和 48.4%。

要点

  • MARCQI 于 2019 年 3 月向参与医院和医生推荐基于证据的阿片类药物疼痛路径。
  • 所有组别及所有时间段出院 OME 处方量均显著下降(P < .001)。
  • 从首月至末月,全髋关节置换术初治患者 OME 下降 47.1%,耐受患者下降 53.4%;全膝关节置换术初治患者下降 48.3%,耐受患者下降 48.4%。

核心结论

  • MARCQI 疼痛控制优化路径(POP)项目成功大幅减少阿片类药物处方并具有持久效果,显著降低了关节置换术患者的总体阿片类药物处方负担。

研究设计与样本

  • 利用 MARCQI 数据库的回顾性分析,收集 2018 年 1 月至 2019 年 12 月所有初次关节置换术患者出院时口服吗啡当量(OME)处方量,比较 2018 年 7 月密歇根州阿片类药物法律实施前后及 2019 年 3 月 MARCQI 推荐发布前后的变化。

主要发现

  • 共纳入 84,998 例关节置换术:阿片类药物初治全髋关节置换术 22,774 例,阿片类药物耐受全髋关节置换术 9,124 例,阿片类药物初治全膝关节置换术 40,882 例,阿片类药物耐受全膝关节置换术 12,218 例;所有组别及所有时间段处方量均显著下降(P < .001);从收集首月至末月,全髋关节置换术阿片类药物初治患者 OME 下降 47.1%,阿片类药物耐受患者下降 53.4%;全膝关节置换术阿片类药物初治患者 OME 下降 48.3%,阿片类药物耐受患者下降 48.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2019, the Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) recommended an evidence-based opioid pain pathway to participating physicians and hospitals for patients undergoing total joint arthroplasty (TJA). The purpose of this study was to determine if the education could influence and have lasting effects on the prescribing patterns for TJA patients. METHODS: Using the MARCQI database, the number of oral morphine equivalents (OMEs) prescribed at discharge were collected from January 2018 through December 2019 for all primary arthroplasty procedures. Periods compared included before and after July 2018 Michigan opioid laws as well as before and after the March 2019 MARCQI recommendations. The data compared total hip arthroplasty (THA) and total knee arthroplasty (TKA) patients, opioid-naive vs opioid-tolerant patients, individual surgeons, and MARCQI sites. RESULTS: The data included 84,998 TJAs: 22,774 opioid-naive THAs, 9124 opioid-tolerant THAs, 40,882 opioid-naive TKAs, and 12,218 opioid-tolerant TKAs. In all the groups and at all time periods there were a significant decrease in prescriptions (P < .001). Individual surgeons and participating sites also demonstrated decreased OMEs on discharge after the recommendations. Between the first and last months of collection, this represented an overall decrease of opioid OMEs for THA by 47.1% for opioid-naive patients and 53.4% for opioid-tolerant patients. For TKA patients, the OME decrease was 48.3% for opioid-naive patients, and 48.4% for opioid-tolerant patients. CONCLUSION: The MARCQI pain control optimization pathway (POP) program has been successful in drastically reducing opioid prescribing with lasting effects, which has substantially limited the overall opioid prescription burden for patients undergoing arthroplasty.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Layson JT, Markel DC, Hughes RE, et al. John N. Insall Award: MARCQI's Pain-Control Optimization Pathway (POP): Impact of Registry Data and Education on Opioid Utilization. J Arthroplasty. 2022. PMID: 35271973. doi:10.1016/j.arth.2022.02.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。